Elotuzumab is a mAb interacting with the glycoprotein signaling lymphocytic activation molecule F7 (SLAM-F7, also named CS1 or CD319) expressed on malignant plasma cells.Notably, SLAM-F7 is also expressed on NK cells, and it has been reported that Elotuzumab enhances NK cell-mediated anti-myeloma activity by directly activating NK cells, inducing ADCC and disrupting the stromal/MM cell interaction [46,47,48,49,50,51]. The gene discussed is SLAMF7; the disease is plasma cell myeloma.